Adding apalutamide (Erleada) to androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer reduced the risk of developing metastases and castration-resistant disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback